Skip to Content

NIH Fellows Award for Research Excellence (FARE) Presentations by Drs. Sklavos, Gu, and Camargo

Presentations by NIH FARE Winners

 

Martha Sklavos, Ph.D., Postdoctoral Fellow, HPV Immunology Laboratory, Infections and Immunoepidemiology Branch (IIB), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI)

Title: Anti-Müllerian Hormone Deficiency in Inherited Bone Marrow Failure Syndromes

Description: Dr. Sklavos is currently interested in evaluating anti-Müllerian Hormone (AMH) as a potential biomarker of cancer risk.  She is leading several studies to further define the role of this novel biomarker in multiple cancer types.  Dr. Sklavos will present AMH data for three inherited bone marrow failure syndromes (IBMFS):  Fanconi Anemia (FA), Dyskeratosis Congenita (DC), and Diamond-Blackfan Anemia (DBA) with a focus on female FA patients.  

Fangyi Gu, M.Med., Sc.D., Postdoctoral Fellow, Genetic Epidemiology Branch, DCEG, NCI

Title: Time to first cigarette after waking and lung cancer

Description: In a study using data from EAGLE (Environment And Genetics in Lung Cancer Etiology) and PLCO,  Dr. Gu established that nicotine dependency, assessed by a simple question of quantitating Time To First Cigarette (TTFC) after awakening in the morning, is a independent lung cancer risk factor that persists after adjustment for other smoking metrics.  TTFC increased lung cancer stratification beyond smoking intensity, duration and pack-years, and therefore has the potential for improving lung cancer prediction based on easily available smoking information.

Constanza Camargo., Ph.D., M.S., M.H.A., Research Fellow, IIB, DCEG, NCI

Title: Epstein-Barr virus (EBV) and gastric cancer: epidemiological findings from the NCI International EBV-Gastric Cancer Consortium

Description: Dr. Camargo’s research focuses on epidemiology of gastric cancer. In this talk, she will present results of her research on the role of EBV infection in gastric carcinogenesis. In particular, Dr. Camargo will discuss determinants of tumor EBV positivity, association of EBV status with survival after cancer diagnosis, and antibody profiles distinguishing patients with EBV-positive and -negative tumors.